nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Cannabidiol May Help Individuals with Cannabis Use Disorder
August 9, 2020   

Research in the area of pharmacological treatment for cannabis use disorder is scarce. In a recent study, conducted between May 2014 and August 2015, cannabidiol (CBD) was tested as a possible treatment. The phase 2a, double-blind, placebo-controlled, randomized...
 Continue reading
FDA Requiring Labeling Changes for Opioid Pain Medicines, Opioid Use Disorder Medicines Regarding Naloxone
August 3, 2020   

The U.S. Food and Drug Administration has reported new requirements affecting prescriptions for opioid pain medicines and medicines to treat opioid use disorder, with the goal to help reduce opioid overdose and death. Labeling for these medicines will...
 Continue reading (Members only)
Biogen Submits Application for US Approval for Alzheimer Drug
July 27, 2020   

Biogen completed the submission of a Biologics License Application for its monoclonal antibody aducanumab to the US Food and Drug Administration for the treatment of Alzheimer’s disease...
 Continue reading (Members only)
Psychotropic Medications and COVID-19
July 20, 2020   

As COVID-19 spreads worldwide, there are many questions arising in terms of how best to care for individuals who are infected. In this comprehensive article, Bilbul and colleagues explore some of the various concerns in terms of the potential impact of psychotropic medications on the various organ systems that are often affected by COVID-19 as well as how psychotropic medications may interact with...
 Continue reading
Brain Connectivity in Cannabis Users
July 17, 2020   

In a recent study, researchers examined brain functional connectivity in 54 adult cannabis users and 90 controls during a cannabis cue exposure task while undergoing functional magnetic resonance imaging. Changes in dynamic connectivity were...
 Continue reading
NEI Virtual Poster Library is Live!
July 13, 2020   

NEI has launched a Virtual Poster Library to fulfill the needs of poster presenters who had hoped to share their research and findings at medical conferences that have been cancelled due to the COVID-19 pandemic....
 Continue reading
US Preventive Services Task Force Recommends Screening Adults for Unhealthy Drug Use
July 10, 2020   

The United States Preventive Services Task Force has released updated recommendations regarding screening for unhealthy drug use in primary care settings among adults (including pregnant and postpartum women) and adolescents who...
 Continue reading (Members only)
Reproducible Epigenetic Marker for Schizophrenia
July 6, 2020   

A recent case-control study examined whether there is a combined contribution of methylation differences associated with Schizophrenia, similar to a polygenic risk score It also tested whether...
 Continue reading
Interagency Autism Coordinating Committee Releases 2019 Summary of Advances in Autism Spectrum Disorder Research
July 2, 2020   

In a recent study, multi-paradigm functional magnetic resonance imaging (fMRI) data from the North American Prodrome Longitudinal Study consortium was analyzed to examine differences in brain connectivity in patients who converted to schizophrenia versus those who did not. ...
 Continue reading (Members only)
FDA Permits Marketing of First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD
June 29, 2020   

The US Food and Drug Administration has recently approved use of a game-based digital device for the treatment of ADHD in youths aged 8-12 years...
 Continue reading
12345678910...
Top of Page